Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells

被引：25
作者：
Luzzatto, L [1 ]
Melo, JV [1 ]
机构：
[1] Hammersmith Hosp, Imperial Coll Sci Technol & Med, Dept Haematol, London W12 0NN, England
来源：
BLOOD | 2002年 / 100卷 / 03期
关键词：
D O I：
10.1182/blood-2002-05-1578
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1105 / 1105
页数：1
相关论文
共 13 条
[1]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
[2]   Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Goldman, JM ;
Melo, JV .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1084-1086
[3]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[4]  
Hochhaus A, 2001, SCIENCE, V293, P2163
[5]   Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation [J].
Hofmann, WK ;
Jones, LC ;
Lemp, NA ;
de Vos, S ;
Gschaidmeier, H ;
Hoelzer, D ;
Ottmann, OG ;
Koeffler, HP .
BLOOD, 2002, 99 (05) :1860-1862
[6]  
Kreil S, 2001, BLOOD, V98, p435A
[7]   Mechanisms of resistance to imatinib (ST1571) and prospects for combination with conventional, chemotherapeutic agents [J].
Krystal, GW .
DRUG RESISTANCE UPDATES, 2001, 4 (01) :16-21
[8]   Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571:: diverse mechanisms of resistance [J].
Mahon, FX ;
Deininger, MWN ;
Schultheis, B ;
Chabrol, J ;
Reiffers, J ;
Goldman, JM ;
Melo, JV .
BLOOD, 2000, 96 (03) :1070-1079
[9]   ST1571: A paradigm of new agents for cancer therapeutics [J].
Mauro, MJ ;
O'Dwyer, M ;
Heinrich, MC ;
Druker, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :325-334
[10]  
RAMIREZ DM, 2001, INT J ONCOL, V19, P5
12